三陰性乳癌術前術後免疫療法可改善總生存期：ESMO 會議結果分享 Perioperative Immunotherapy Improves Overall Survival in TNBC

在本次ESMO會議中，最新的研究結果顯示，針對三陰性乳癌患者進行術前和術後的免疫療法，能夠顯著改善總生存期（OS）。三陰性乳癌因其缺乏標靶治療的受體，治療選擇相對有限，免疫療法的加入為這類患者提供了新的希望。影片將深入探討這項研究結果，並解釋免疫療法如何影響治療效果及病人的存活率。

In this ESMO meeting, the latest findings reveal that perioperative immunotherapy significantly improves overall survival (OS) in patients with triple-negative breast cancer. As triple-negative breast cancer lacks receptor targets for standard therapies, treatment options are limited. The addition of immunotherapy offers new hope for patients. This video will delve into the study's findings and explain how immunotherapy can enhance treatment outcomes and patient survival.